{"id":"W4411643311","doi":"10.1016/j.esmoop.2025.105200","title":"71O Profiling antibody-drug conjugate (ADC) target expression in high-grade serous ovarian cancer (HGSOC): Opportunities for targeted treatment strategies","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; BeiGene; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; European Commission; Seagen; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Amgen; Deciphera Pharmaceuticals; Sociedad Española de Oncología Médica; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Mersana Therapeutics; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Serous ovarian cancer; Antibody-drug conjugate; Serous fluid; Ovarian cancer; Medicine; Conjugate; Cancer research; Drug; Antibody; Targeted therapy; Oncology; Monoclonal antibody; Internal medicine; Cancer; Immunology; Pharmacology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002389162,0.0003681688,0.0007675387,0.0001895393,0.0001985662,0.0002164562,0.0002415046,0.000124377,0.0003360886],"category_scores_gemma":[0.00001928873,0.000284294,0.000120839,0.0002181027,0.00006635005,0.0003481997,0.0001275557,0.000132077,0.000005370433],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005614921,"about_ca_system_score_gemma":0.001325288,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01426823,"about_ca_topic_score_gemma":0.00200232,"domain_scores_codex":[0.99817,0.00009581371,0.0004840578,0.0006027861,0.0001768688,0.0004704529],"domain_scores_gemma":[0.999032,0.0001244386,0.0001523128,0.0004425742,0.0001047122,0.0001439778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0125412,0.01675886,0.61487,0.004116853,0.007606705,0.003847483,0.01183258,0.003979512,0.04207664,0.1557869,0.06123215,0.06535116],"study_design_scores_gemma":[0.05135664,0.002057418,0.1845063,0.005579246,0.001206665,0.00001806046,0.01291347,0.001133218,0.5802096,0.01119877,0.1485065,0.001314145],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9204941,0.004604061,0.0004848415,0.04121086,0.001828048,0.01241272,0.001031238,0.0002402421,0.01769391],"genre_scores_gemma":[0.9760842,0.001997298,0.00907308,0.0009479878,0.0001641235,0.003525854,0.001041414,0.00005245517,0.007113593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.538133,"threshold_uncertainty_score":0.9999609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0628592540817787,"score_gpt":0.3691242001253307,"score_spread":0.306264946043552,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}